Literature DB >> 20932637

Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer.

Firas Abdollah1, Maxine Sun, Rodolphe Thuret, Lars Budäus, Claudio Jeldres, Markus Graefen, Alberto Briganti, Paul Perrotte, Patrizio Rigatti, Francesco Montorsi, Pierre I Karakiewicz.   

Abstract

BACKGROUND: At radical prostatectomy (RP), pelvic lymph node dissection (PLND) represents the most accurate staging procedure for the presence of lymph node (LN) metastases.
OBJECTIVE: We evaluated the rate of PLND use and its lymph node count (LNC) over the last two decades. We also tested the relationship between LNC and the rate of pN1 stage. DESIGN, SETTING, AND PARTICIPANTS: Between 1988 and 2006, 130,080 RPs were recorded in 17 Surveillance Epidemiology and End Results registries. MEASUREMENTS: The statistical significance of temporal trends was evaluated with the chi-square trend test. Separate univariable and multivariable regression analyses tested the relationship between predictors and two end points: (1) lack of LN staging (pNx) and (2) presence of LN metastases (pN1). RESULTS AND LIMITATIONS: Stage pNx was recorded in 25.9% of patients, and pNx rate was higher in more contemporary years (30.1% in 2000-2006 vs 20.8% in 1988-1993; multivariable p < 0.001). When PLND was performed, an average of 7.4 LNs (median: 6) were removed. The average LNC decreased from 12.0 nodes (median: 12) in 1988 to 6.0 nodes (median: 4) in 2006. Overall pN1 rate was 3.4% and decreased from 10.7% to 3.1% between 1988 and 2006 (p < 0.001). LNC was an independent predictor of pN1 stage (multivariable p < 0.001).
CONCLUSIONS: An increasingly larger proportion of prostate cancer patients remain without LN staging at RP. Fewer LNs were removed at PLND over time, resulting in fewer patients diagnosed with pN1 stage at RP. The impact of this phenomenon on cancer control outcomes is still to be verified.
Copyright © 2010 European Association of Urology. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20932637     DOI: 10.1016/j.eururo.2010.09.029

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

1.  Sentinel lymph node dissection combined with meticulous histology increases the detection rate of nodal metastases in prostate cancer.

Authors:  Michal Staník; Ivo Čapák; Daniel Macík; Jiří Vašina; Eva Lžičařová; Jiří Jarkovský; Martin Šustr; David Miklánek; Jan Doležel
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

2.  Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.

Authors:  Changhoon Song; Hyun-Cheol Kang; Jae-Sung Kim; Keun-Yong Eom; In Ah Kim; Jin-Beom Chung; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  Strahlenther Onkol       Date:  2015-07-10       Impact factor: 3.621

3.  Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.

Authors:  Giorgio Brembilla; Paolo Dell'Oglio; Armando Stabile; Alessandro Ambrosi; Giulia Cristel; Lisa Brunetti; Anna Damascelli; Massimo Freschi; Antonio Esposito; Alberto Briganti; Francesco Montorsi; Alessandro Del Maschio; Francesco De Cobelli
Journal:  Eur Radiol       Date:  2017-12-21       Impact factor: 5.315

4.  Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.

Authors:  Piotr Zareba; James Eastham; Peter T Scardino; Karim Touijer
Journal:  J Urol       Date:  2017-06-15       Impact factor: 7.450

5.  Significance of examined lymph-node count in accurate staging and long-term survival in patients undergoing radical prostatectomy: a population-based study.

Authors:  Cheng Chen; Jie Shen; Zhaoyu Xing; Changchuan Jiang; Linkun Hu; Li Cui; Dong Xue; Xiaozhou He; Renfang Xu
Journal:  Int Urol Nephrol       Date:  2019-09-30       Impact factor: 2.370

6.  Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy.

Authors:  Avinash Chenam; Jaspreet S Parihar; Nora Ruel; Sumanta Pal; Yvonne Avila; Jonathan Yamzon; Clayton Lau; Bertram Yuh
Journal:  J Robot Surg       Date:  2017-09-13

7.  Detection of Lymph Node Metastases with SERRS Nanoparticles.

Authors:  Massimiliano Spaliviero; Stefan Harmsen; Ruimin Huang; Matthew A Wall; Chrysafis Andreou; James A Eastham; Karim A Touijer; Peter T Scardino; Moritz F Kircher
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

Review 8.  [Salvage lymphadenectomy in patients with prostate cancer recurrence: A review].

Authors:  D K Osmonov; A V Aksenov; C A Jilg; W Schultze-Seeman; C M Naumann; M F Hamann; K Bothe; K-P Jünemann
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

9.  A clinicogenetic model to predict lymph node invasion by use of genome-based biomarkers from exome arrays in prostate cancer patients.

Authors:  Jong Jin Oh; Seunghyun Park; Sang Eun Lee; Sung Kyu Hong; Sangchul Lee; Hak Min Lee; Jeung Keun Lee; Jin-Nyoung Ho; Sungroh Yoon; Seok-Soo Byun
Journal:  Korean J Urol       Date:  2015-02-02

10.  Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment.

Authors:  L A Kluth; F Abdollah; E Xylinas; M Rieken; H Fajkovic; C Seitz; M Sun; P I Karakiewicz; P Schramek; M P Herman; A Becker; J Hansen; B Ehdaie; W Loidl; K Pummer; R K Lee; Y Lotan; D S Scherr; D Seiler; S A Ahyai; F K-H Chun; M Graefen; A Tewari; A Nonis; A Bachmann; F Montorsi; M Gönen; A Briganti; S F Shariat
Journal:  Br J Cancer       Date:  2014-07-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.